ClinicalTrials.gg
CompletedNCT05697510SILTUXILAMUpdated Nov 13, 2026

Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM

A Phase 1 interventional study of Siltuximab in Acute Myeloid Leukemia (AML), sponsored by Nantes University Hospital. Completed at 1 site in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Nantes University Hospital · Phase 1, Interventional, and Treatment

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Leukemia, Myeloid, Acute by Nantes University Hospital — 4 open to participants now, 4 under way, none of them phase 3. Leukemia, Myeloid, Acute · Nantes University Hospital.

Enrollment
6th of 10
12 · median 21
Started
2023
with 1 other
Phase 1
4 of 13
1 open now
Registered
9th of 13
by date

Among the 13 studies in Leukemia, Myeloid, Acute by Nantes University Hospital, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 in phase 1, and was the 9th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 13 studies in Leukemia, Myeloid, Acute by Nantes University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Leukemia, Myeloid, Acute by Nantes University Hospital, or all of them as a file.
02

Study summary

This is a phase 1 dose escalation study testing the addition of an anti-IL6 (siltuximab) to standard induction chemotherapy for high-risk AML.

Read the detailed description

Administration of siltuximab at day 8 of induction following a classical induction using idarubicin 8mg/m2/d for 5 days and cytarabine 100mg/m2/d for 7 days.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • AML IL-6 SILTUXIMAB
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age >= 18 years
  • AML with a poor prognosis defined according to the criteria below:

LAM : Age \<60 years and unfavorable risk according to the 2017 ELN Age> = 60 years old and intermediate or unfavorable risk according to the ELN 2017 LAM in Relapse: whatever the age

  • \<= 2
  • Patient eligible for intensive chemotherapy
  • Liver function tests: transaminases \<3x normal, \<1.5X normal
  • > 60ml / min
  • > = 50%

Exclusion criteria

Exclusion Criteria:

  • Patients with FLT3 ITD or TKD mutation eligible for FLT3 inhibitor therapy
  • Uncontrolled infection
  • Hep B, C, +
  • History of diverticulosis / diverticulitis
  • Patients at high risk of gastrointestinal perforation
  • No social security or any other scheme
  • Pregnant women or patient unable to take (pill, abstinence, IUD not allowed) in case of fertility. contraceptive pill, abstinence, unauthorised IUD) in case of fertility. A patient who cannot continue contraception for at least 3 months after the last SILTUXIMAB injection is not eligible for inclusion.
  • Lactating women
  • Minors
  • Adults under guardianship, curatorship or legal protection
  • to one of the active substances or to one of the
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    SILTUXIMAB

    Drug: Siltuximab

Interventions

  • Administration of siltuximab at day 8 of induction following a classical induction; 3 dose levels : 7, 9 and 11mg/kg

06

What researchers measure

Primary outcomes

  1. number of DLT

    Time frame: 45 days

Secondary outcomes

  1. Evaluation of the response to induction therapy with idarubicin + cytarabine + siltuximab

    Calculation of complete remission (CR) and CR with incomplete recovery (CRi) according to the ELN 2017 definition

    Time frame: Day 30 and Day 45

  2. Evaluation of response at D15 after induction

    percent bone marrow blasts at D15 (myelogram)

    Time frame: Day 15

  3. Assessment of myelotoxicity

    Neutrophil recovery time (\>1.0 × 109/L) from D1; Platelet recovery time (\>100 × 109/L) from D1

    Time frame: Day 45

  4. Overall survival

    delay from D1 of induction to date of last news or death

    Time frame: Month 6

  5. Leukaemia-free survival

    delay between the date of CR and the date of relapse or death or the date of the last follow-up

    Time frame: Month 6

  6. Event-free survival

    delay between D1 of induction and the date of relapse, death or date of last

    Time frame: Month 6

  7. Incidence of relapse if remission

    relapse rate at last follow-up

    Time frame: Month 6

  8. Infections

    monitoring of AEs infection

    Time frame: Month 6

  9. Cytokine levels: FLT3L and IL-6

    Cytokine levels: FLT3L and IL-6

    Time frame: Day 1, Day 8, Day 15, Day 22

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in May 2026, 37 months.

Of 307 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 87. This study's 37 months is below that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Jun 2025 → May 2026 and completion Jun 2025 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2023
First posted
Jan 26, 2023
StartActual
Mar 16, 2023
Primary completionActual
May 4, 2026was Jun 2025
CompletionActual
May 4, 2026was Jun 2025
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Primary completion
Jun 30, 2025→May 4, 2026 (actual)
Nov 13, 2026
Study completion
Jun 30, 2025→May 4, 2026 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    Primary completion Jun 30, 2025→May 4, 2026 (now actual)
    Study completion Jun 30, 2025→May 4, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05697510
Responsible party
Sponsor
First posted
Jan 26, 2023
Start date
Mar 16, 2023
Primary completion
May 4, 2026
Completion
May 4, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siltuximab

Start the discussion